Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma.

Trial Profile

Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2011

At a glance

  • Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Mar 2009 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 13 Mar 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov, last updated 13 Mar 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top